AEST.MED.INT.HLD.SP.ADR/3 (3FMA) — Capital Reinvestment Ratio
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Capital Reinvestment Ratio of 0.39x as of December 2024, meaning it reinvests 0% of its operating cash flow (€79.67 Million) in capital expenditures (€30.79 Million). See AEST.MED.INT.HLD.SP.ADR/3 balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
AEST.MED.INT.HLD.SP.ADR/3 Capital Reinvestment Ratio (2021–2024)
This chart tracks AEST.MED.INT.HLD.SP.ADR/3's Capital Reinvestment Ratio across 3 annual periods. Check AEST.MED.INT.HLD.SP.ADR/3 (3FMA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for AEST.MED.INT.HLD.SP.ADR/3 (2021–2024)
Year-by-year Capital Reinvestment Ratio for AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2024. For live market cap and broader valuation context, see market cap of AEST.MED.INT.HLD.SP.ADR/3.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.39x | €79.67 Million | €30.79 Million | ▼ -48.2% |
| 2023 | 0.75x | €74.29 Million | €55.46 Million | ▲ +14.1% |
| 2021 | 0.65x | €51.09 Million | €33.44 Million | — |